Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Reduced Intensity Vs. Standard Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with MDS or Secondary AML: A Prospective, Randomized Phase III Study of the Chronic Malignancies Working Party of the EBMT (RICMAC-Trial)

Blood (2014) 124 (21): 320.

https://doi.org/10.1182/blood.V124.21.320.320

Published: 2014

Journal Articles

Disruption of TP53 function by Point Mutations and Deletions Is Associated with An Increased Risk of Disease Progression within Previously Treated, Relapsed Chronic Lymphocytic Leukemia Patients

Blood (2011) 118 (21): 2445.

https://doi.org/10.1182/blood.V118.21.2445.2445

Published: 2011

Journal Articles

Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,

Blood (2011) 118 (21): 3521.

https://doi.org/10.1182/blood.V118.21.3521.3521

Published: 2011

Journal Articles

Assessment of Minimal Residual Disease (MRD) In Relapsed CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab (REACH)

Blood (2010) 116 (21): 1390.

https://doi.org/10.1182/blood.V116.21.1390.1390

Published: 2010

Journal Articles

Effect of FCGR2A and FCGR3A variants on CLL outcome

Blood (2010) 116 (20): 4212–4222.

https://doi.org/10.1182/blood-2010-03-272765

Published: 2010

Journal Articles

FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone.

David Dornan, Ph.D, Olivia Spleiss, Ph.D, Ru-Fang T Yeh, PhD, Guillemette Duchateau-Nguyen, PhD, Tadeusz Robak, Sergey I Moiseev, MD, Anna Dmoszynska, MD, Philippe Solal-Celigny, MD, Krzysztof Warzocha, MD, PhD, Javier Loscertales, MD, John Catalano, MD, Boris V Afanasiev, MD, Loree Larratt, MD, Viktor A Rossiev, MD, PhD, Isabelle Bence-Bruckler, MD, FRCPC, Christian H. Geisler, MD, DMSc, Marco Montillo, MD, Michael K. Wenger, MD, Martin Weisser, MD

Blood (2009) 114 (22): 2338.

https://doi.org/10.1182/blood.V114.22.2338.2338

Published: 2009

Journal Articles

Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial

Tadeusz Robak, MD, PhD, Sergey I Moiseev, MD, Anna Dmoszynska, MD, Philippe Solal-Céligny, MD, Krzysztof Warzocha, MD, PhD, Javier Loscertales, MD, John Catalano, MD, Boris V Afanasiev, MD, Loree Larratt, MD, Christian Geisler, MD, DMSc, Marco Montillo, MD, Peter Ganly, BMBCh, PhD, Caroline Dartigeas, MD, András Rosta, MD, PhD, Ann Janssens, MD, Myriam Mendila, MD, Jörg Maurer, Michael K. Wenger, MD

Blood (2008) 112 (11): lba-1.

https://doi.org/10.1182/blood.V112.11.lba-1.lba-1

Published: 2008

Journal Articles

Multicenter Experience of High Dose Chemotherapy (HDCT)+Autologous Stem Cell Transplantation (ASCT) in Multiple Sclerosis (MS) Patients.

Blood (2006) 108 (11): 3072.

https://doi.org/10.1182/blood.V108.11.3072.3072

Published: 2006

Journal Articles

Treatment Outcomes in Multiple Sclerosis (MS) Patients after Early, Conventional and Salvage High Dose Chemotherapy (HDCT)+Autologous Stem Cell Transplantation (ASCT).

Yury L. Shevchenko, Andrei A. Novik, Boris V. Afanasiev, Igor A. Lisukov, Tatiana I. Ionova, PhD, Andrei D. Kulagin, MD, Olga A. Malysheva, MD, Gennady N. Bisaga, MD, PhD, Vladimir J. Melnichenko, MD, PhD, Sergei V. Voloshin, MD, PhD, Denis A. Fedorenko, MD, PhD, Inna V. Vereschagina, MD, Anton V. Kishtovich, PhD, Yury N. Fedotov, MD, PhD, Gary I. Gorodokin, MD

Blood (2005) 106 (11): 5467.

https://doi.org/10.1182/blood.V106.11.5467.5467

Published: 2005

Journal Articles

Clinical and Quality of Life Outcomes in Patients with Multiple Sclerosis (MS) after High Dose Chemotherapy(HDCT)+Autologous Stem Cell Transplantation (ASCT).

Yury L. Shevchenko, Andri A. Novik, Boris V. Afanasiev, Igor A. Lisukov, Yury N. Fedotov, MD, Tatiana I. Ionova, PhD, Alexandr D. Kulagin, PhD, Olga A. Malysheva, MD, Gennadi N. Bisaga, PhD, Vladimir Y. Melnichenko, PhD, Lubov V. Chelombit, MD, Sergei V. Voloshin, PhD, Denis A. Fedorenko, PhD, Inna V. Vereschagina, MD, Anton V. Kishtovich, PhD

Blood (2004) 104 (11): 1875.

https://doi.org/10.1182/blood.V104.11.1875.1875

Published: 2004

NARROW

Reduced Intensity Vs. Standard Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with MDS or Secondary AML: A Prospective, Randomized Phase III Study of the Chronic Malignancies Working Party of the EBMT (RICMAC-Trial)

Disruption of TP53 function by Point Mutations and Deletions Is Associated with An Increased Risk of Disease Progression within Previously Treated, Relapsed Chronic Lymphocytic Leukemia Patients

Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,

Assessment of Minimal Residual Disease (MRD) In Relapsed CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab (REACH)

Effect of FCGR2A and FCGR3A variants on CLL outcome

FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone.

Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial

Multicenter Experience of High Dose Chemotherapy (HDCT)+Autologous Stem Cell Transplantation (ASCT) in Multiple Sclerosis (MS) Patients.

Treatment Outcomes in Multiple Sclerosis (MS) Patients after Early, Conventional and Salvage High Dose Chemotherapy (HDCT)+Autologous Stem Cell Transplantation (ASCT).

Clinical and Quality of Life Outcomes in Patients with Multiple Sclerosis (MS) after High Dose Chemotherapy(HDCT)+Autologous Stem Cell Transplantation (ASCT).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only